Provided by Tiger Trade Technology Pte. Ltd.

Aspire Biopharma Holdings Inc.

1.59
+0.160011.19%
Post-market: 1.45-0.1400-8.81%19:51 EST
Volume:297.41K
Turnover:454.67K
Market Cap:5.50M
PE:-0.02
High:1.63
Open:1.43
Low:1.36
Close:1.43
52wk High:420.00
52wk Low:1.20
Shares:3.46M
Float Shares:3.08M
Volume Ratio:0.13
T/O Rate:9.67%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-65.9600
EPS(LYR):-0.1190
ROE:--
ROA:-195.11%
PB:-0.48
PE(LYR):-13.36

Loading ...

Feb 18, 2026

Public Prospectus

Form S-1 - General form for registration of securities under the Securities Act of 1933
Feb 12, 2026

Major Issues Report

Form 8-K - Current report
Feb 06, 2026

Major Issues Report

Form 8-K - Current report
Jan 30, 2026

Major Issues Report

Form 8-K - Current report
Jan 15, 2026

Major Issues Report

Form 8-K - Current report
Jan 14, 2026

Major Issues Report

Form 8-K - Current report
Jan 06, 2026

Major Issues Report

Form 8-K - Current report
Dec 03, 2025

Public Prospectus

Form S-1 - General form for registration of securities under the Securities Act of 1933
Nov 15, 2025

[Rev.]Quaterly Report

Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]
Nov 14, 2025

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 14, 2025

Major Issues Report

Form 8-K - Current report
Nov 05, 2025

Major Issues Report

Form 8-K - Current report
Oct 17, 2025

Major Issues Report

Form 8-K - Current report
Sep 27, 2025

Correspondence

Form CORRESP - Correspondence
Sep 26, 2025

Major Issues Report

Form 8-K - Current report
Sep 26, 2025

[Amend]Public Prospectus

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
Sep 18, 2025

Public Prospectus

Form S-1 - General form for registration of securities under the Securities Act of 1933
Aug 22, 2025

Major Issues Report

Form 8-K - Current report
Aug 13, 2025

[Rev.]Quaterly Report

Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]
Aug 13, 2025

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]